ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review

Xie, Zeyu; Yang, Sensen; Deng, Weishang; Li, Jinjian; Chen, Jisheng*广东药学院; 1
Clinical Epidemiology2022DOI: 10.2147/CLEP.S391819
8被引12阅读
引用收藏
分享

摘要

Purpose: The effect and safety of Semaglutide and Liraglutide on weight loss in people with obesity or overweight were evaluated by a Network Meta-Analysis system to provide an evidence-based reference for clinical treatment. Methods: Computer searched PubMed, Embase, and Cochrane Library databases to collect Liraglutide and Semaglutide injection Results: Twenty-three RCTs study with 11,545 patients and 4 interventions (semaglutide 2.4mg, semaglutide 1.0mg, liraglutide 3.0mg and liraglutide 1.8 mg) were finally included. In terms of efficacy, semaglutide 2.4mg (-12.47 kg) had the best weight loss, followed by liraglutide 3.0mg (-5.24 kg), semaglutide 1.0mg (-3.74 kg) and liraglutide 1.8mg (-3.29 kg). In terms of decreased HbA1c, semaglutide 2.4mg (MD=-1.48%, 95% CI [-1.93, -1.04]), semaglutide 1.0mg (MD=-1.36%, 95% CI [-1.72, -1.01]), liraglutide 1.8mg (MD=-1.23%, 95%Cl [-1.66, -0.80]) more effective than placebo. In terms of safety, the total incidence of adverse events was semaglutide 2.4mg > liraglutide 3.0mg > liraglutide 1.8mg > semaglutide 1.0mg compare to placebo, the incidence of serious adverse events was liraglutide 3.0mg > liraglutide 1.8mg > semaglutide 2.4mg > semaglutide 1.0mg, the incidence of hypoglycemic events was semaglutide 2.4mg > liraglutide 3.0mg > semaglutide 1.0mg > liraglutide 1.8mg. Conclusion: This meta-analysis indicates that all GLP-1RAs were more efficacious than placebo in people with obesity or overweight on efficacy. Semaglutide 2.4mg has an absolute advantage in weight loss and decreased HbA1c, but the incidence of total adverse events is also the highest and can cause hypoglycemia. In addition, although liraglutide 3.0mg was less effective than semaglutide 2.4mg, serious adverse events were still the most elevated.

学科与关键词

关键词
glucagon-like peptide-1 receptor agonistsweight losssystematic reviewliraglutidesemaglutide
相关
加载中…
  • Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis
    Zhong, Ping; Zeng, Hai; Huang, Miaochun; Fu, Wenbin*; Chen, Zhixia*ENDOCRINE, 2022, 75(3): 718-724.被引 23
  • Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review
    Xie, Zeyu; Hu, Jia; Gu, Hangye; Li, Mengting; Chen, Jisheng*Frontiers in Endocrinology, 2023, 14: 1244432.被引 1
  • Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis
    Li, Aihua; Su, Xiaorong; Hu, Shanshan*; Wang, Yong*Diabetes Research and Clinical Practice, 2023, 198: 110605.被引 6
查看全部 →

发表信息

论文状态
公开发表
期刊
Clinical Epidemiology
发表日期
2022
卷期
第 14 卷
页码
1463-1476
DOI
10.2147/CLEP.S391819
期刊等级
2区
成果收录
SCIE
资助标注
National Key Specialty Construction Project (Clinical Pharmacy); High-level Clinical Key Specialty of Guangdong Province; Guangzhou Minsheng Science and Technology Research Program Project [201803010096]; fund for the improvement of medical services and guarantee capacity [Z155080000004]

作者

  • X

    Xie, Zeyu (第一作者)

    1 · guangdong pharmaceut univ

  • Y

    Yang, Sensen

    1 · guangdong pharmaceut univ

查看全部 5 位作者收起作者
  • D

    Deng, Weishang

    1 · guangdong pharmaceut univ

  • L

    Li, Jinjian

    1 · guangdong pharmaceut univ

  • C

    Chen, Jisheng (通讯)

    1 · guangdong pharmaceut univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417